ClinicalTrials.Veeva

Find clinical trials for Lung Cancer in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Lung Cancer trials near Washington, DC, USA:

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Bethesda, Maryland, United States and 64 other locations

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo

Chevy Chase, Maryland, United States and 83 other locations

chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Osimertinib
Drug: Carboplatin

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Baltimore, Maryland, United States and 14 other locations

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo

Fairfax, Virginia, United States and 47 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Baltimore, Maryland, United States and 41 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a
Drug: Docetaxel

Phase 3

Daiichi Sankyo

Bethesda, Maryland, United States and 205 other locations

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC)...

Begins enrollment in 3 months
Small-cell Lung Cancer
Small Cell Lung Carcinoma
Drug: Onvansertib

Phase 2

Taofeek Owonikoko

Baltimore, Maryland, United States

Locations recently updated

with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Cisplatin
Drug: Datopotamab Deruxtecan

Phase 3

Daiichi Sankyo

Bethesda, Maryland, United States and 139 other locations

This is a study for patients with advanced non-small cell lung cancer with changes to their cancer cells called EGFR mutat ...

Active, not recruiting
Nonsmall Cell Lung Cancer
EGFR Gene Mutation
Drug: Osimertinib
Drug: Dasatinib

Phase 1, Phase 2

Chul Kim

Washington, District of Columbia, United States and 1 other location

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo

Fairfax, Virginia, United States and 122 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems